This news item is about: In a paradigm-shifting collaborative relationship between Cornell University College of Veterinary Medicine and Vertex Pharmaceuticals, of Cambridge, Mass., Dr. David Russell is expanding the field of options for novel tuberculosis (TB) drug discovery. His long-term goal is to help the many millions around the world who suffer from tuberculosis, the disease caused by Mycobacterium tuberculosis, by finding new compounds that can reduce the treatment time and also be effective against drug-resistant TB. With initial screens of approximately 210,000 compounds (from the pharmaceutical company’s compound library) already finished, he says the collaboration has clearly provided access to new compounds with the potential to stop tuberculosis activity.